BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 29855504)

  • 1. Synthetic Lethality-based Identification of Targets for Anticancer Drugs in the Human Signaling Network.
    Liu L; Chen X; Hu C; Zhang D; Shao Z; Jin Q; Yang J; Xie H; Liu B; Hu M; Ke K
    Sci Rep; 2018 May; 8(1):8440. PubMed ID: 29855504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SL
    Liu Y; Wu M; Liu C; Li XL; Zheng J
    IEEE/ACM Trans Comput Biol Bioinform; 2020; 17(3):748-757. PubMed ID: 30969932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SynLethDB: synthetic lethality database toward discovery of selective and sensitive anticancer drug targets.
    Guo J; Liu H; Zheng J
    Nucleic Acids Res; 2016 Jan; 44(D1):D1011-7. PubMed ID: 26516187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ranking novel cancer driving synthetic lethal gene pairs using TCGA data.
    Ye H; Zhang X; Chen Y; Liu Q; Wei J
    Oncotarget; 2016 Aug; 7(34):55352-55367. PubMed ID: 27438146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthetic lethality on drug discovery: an update on cancer therapy.
    Yar MS; Haider K; Gohel V; Siddiqui NA; Kamal A
    Expert Opin Drug Discov; 2020 Jul; 15(7):823-832. PubMed ID: 32228106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of synthetic lethal pairs in biological systems through network information centrality.
    Kranthi T; Rao SB; Manimaran P
    Mol Biosyst; 2013 Aug; 9(8):2163-7. PubMed ID: 23728082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthetic lethality as an engine for cancer drug target discovery.
    Huang A; Garraway LA; Ashworth A; Weber B
    Nat Rev Drug Discov; 2020 Jan; 19(1):23-38. PubMed ID: 31712683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Link synthetic lethality to drug sensitivity of cancer cells.
    Wang R; Han Y; Zhao Z; Yang F; Chen T; Zhou W; Wang X; Qi L; Zhao W; Guo Z; Gu Y
    Brief Bioinform; 2019 Jul; 20(4):1295-1307. PubMed ID: 29300844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Network of Conserved Synthetic Lethal Interactions for Exploration of Precision Cancer Therapy.
    Srivas R; Shen JP; Yang CC; Sun SM; Li J; Gross AM; Jensen J; Licon K; Bojorquez-Gomez A; Klepper K; Huang J; Pekin D; Xu JL; Yeerna H; Sivaganesh V; Kollenstart L; van Attikum H; Aza-Blanc P; Sobol RW; Ideker T
    Mol Cell; 2016 Aug; 63(3):514-25. PubMed ID: 27453043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Syn-lethality: an integrative knowledge base of synthetic lethality towards discovery of selective anticancer therapies.
    Li XJ; Mishra SK; Wu M; Zhang F; Zheng J
    Biomed Res Int; 2014; 2014():196034. PubMed ID: 24864230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring Proteomic Drug Targets, Therapeutic Strategies and Protein - Protein Interactions in Cancer: Mechanistic View.
    Dar KB; Bhat AH; Amin S; Anjum S; Reshi BA; Zargar MA; Masood A; Ganie SA
    Curr Cancer Drug Targets; 2019; 19(6):430-448. PubMed ID: 30073927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human Interactomics: Comparative Analysis of Different Protein Interaction Resources and Construction of a Cancer Protein-Drug Bipartite Network.
    De Las Rivas J; Alonso-López D; Arroyo MM
    Adv Protein Chem Struct Biol; 2018; 111():263-282. PubMed ID: 29459035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthetic Lethality: From Research to Precision Cancer Nanomedicine.
    Gupta A; Ahmad A; Dar AI; Khan R
    Curr Cancer Drug Targets; 2018; 18(4):337-346. PubMed ID: 28669337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of synthetic lethality based on a functional network by using machine learning algorithms.
    Li J; Lu L; Zhang YH; Liu M; Chen L; Huang T; Cai YD
    J Cell Biochem; 2019 Jan; 120(1):405-416. PubMed ID: 30125975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. INTEGRATING GENETIC AND STRUCTURAL DATA ON HUMAN PROTEIN KINOME IN NETWORK-BASED MODELING OF KINASE SENSITIVITIES AND RESISTANCE TO TARGETED AND PERSONALIZED ANTICANCER DRUGS.
    Verkhivker GM
    Pac Symp Biocomput; 2016; 21():45-56. PubMed ID: 26776172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting synthetic lethal interactions in human cancers using graph regularized self-representative matrix factorization.
    Huang J; Wu M; Lu F; Ou-Yang L; Zhu Z
    BMC Bioinformatics; 2019 Dec; 20(Suppl 19):657. PubMed ID: 31870274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells.
    Gautam P; Karhinen L; Szwajda A; Jha SK; Yadav B; Aittokallio T; Wennerberg K
    Mol Cancer; 2016 May; 15(1):34. PubMed ID: 27165605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Embracing synthetic lethality of novel anticancer therapies.
    Kamal A; Shaik TB; Malik MS
    Expert Opin Drug Discov; 2015 Oct; 10(10):1119-32. PubMed ID: 26211783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic discovery of mutation-specific synthetic lethals by mining pan-cancer human primary tumor data.
    Sinha S; Thomas D; Chan S; Gao Y; Brunen D; Torabi D; Reinisch A; Hernandez D; Chan A; Rankin EB; Bernards R; Majeti R; Dill DL
    Nat Commun; 2017 May; 8():15580. PubMed ID: 28561042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Synthetic Dosage Lethal Genetic Interaction Between CKS1B and PLK1 Is Conserved in Yeast and Human Cancer Cells.
    Reid RJ; Du X; Sunjevaric I; Rayannavar V; Dittmar J; Bryant E; Maurer M; Rothstein R
    Genetics; 2016 Oct; 204(2):807-819. PubMed ID: 27558135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.